Home
/

Dyslipidemia

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Key takeaway:

Dyslipidemia blood testing uses eight markers—LDL, HDL, triglycerides, ApoB, LDL-P, HDL-P, and particle size—to assess atherogenic risk beyond total cholesterol. ApoB (ideally <90 mg/dL) and LDL-P (optimal <1000 nmol/L) are associated with more precise cardiovascular risk assessment than LDL alone. This comprehensive panel may help support precision treatment decisions by linking lipoprotein particle exposure to atherosclerosis and metabolic health.

Read more →
Table of contents

Dyslipidemia and the Particles That Carry Cholesterol

Dyslipidemia biomarkers are the measurable fats and the proteins that carry them in blood, revealing how your body transports and disposes of lipids every day. Core measures capture the main cargo (cholesterol and triglycerides) and the vehicles that move it—low-density, high-density, and very-low-density lipoproteins (LDL, HDL, VLDL). The liver builds and recycles most of these particles, while the intestine contributes after meals (chylomicrons). As VLDL sheds triglyceride, it becomes LDL, a particle that can enter artery walls; HDL helps ferry cholesterol back to the liver (reverse cholesterol transport). Protein “tags” on particles add precision: apolipoprotein B reflects the number of artery-entering particles (apoB-containing lipoproteins), apolipoprotein A-I reflects major HDL scaffolding (apoA-I), and a genetically influenced variant, lipoprotein(a), adds a pro-atherogenic component (Lp(a)). Together, these tests map the balance between lipid delivery, storage, and clearance. They enable clinicians to identify harmful traffic patterns in the bloodstream, personalize nutrition and medication choices, and track whether the body’s lipid flow is moving toward arterial safety.

Reading an Advanced Lipid Panel

Dyslipidemia testing reveals how your body packages and traffics fats through the bloodstream—information that touches the heart and vessels, liver fat handling, pancreatic safety, hormone building blocks, and even inflammation. It is less about one number and more about the number and nature of lipoprotein particles that contact artery walls.Common cut points help frame risk. LDL is best kept toward the lower end (often desirable below 100), while HDL is more protective at the higher end (≥60; low is <40 in men and <50 in women). Triglycerides are safest toward the lower end (normal <150). ApoB, a direct count of atherogenic particles, is ideally low (often <90). LDL-P, another particle count, is optimal toward the lower end (commonly <1000). HDL-P reflects the quantity of HDL particles; higher tends to be favorable. LDL size is categorized as larger (pattern A) versus smaller (pattern B), with larger being better. HDL size generally tracks benefit in the mid-to-larger range.When values are low, the meaning differs by marker. Low LDL, ApoB, and LDL-P indicate fewer artery-penetrating particles; if extremely low, they may reflect hyperthyroidism, malabsorption, or rare genetic variants, sometimes with fatigue or fat-soluble vitamin issues. Very low triglycerides can be normal or reflect hyperthyroidism or undernutrition. Low HDL and HDL-P suggest impaired reverse cholesterol transport, often seen with insulin resistance. In pregnancy, lipids rise physiologically; in children and teens, low HDL and high triglycerides often signal early metabolic risk.Big picture: these markers map energy transport and vascular exposure. They integrate with glucose metabolism, thyroid and liver function, inflammation, and genetics—helping forecast atherosclerosis, pancreatitis risk (when triglycerides are very high), and long-term cardiovascular outcomes.

What a Lipid Workup Can and Can't Settle

Dyslipidemia blood testing provides a window into how your body manages fats, which are essential for energy, hormone production, cell structure, and brain function. Imbalances in blood lipids can disrupt cardiovascular health, metabolism, and even immune and reproductive systems. At Superpower, we measure LDL, HDL, Triglycerides, ApoB, LDL-P, HDL-P, LDL Size, and HDL Size to give a comprehensive view of your lipid profile.LDL (low-density lipoprotein) is often called “bad cholesterol” because high levels can deposit cholesterol in artery walls, increasing cardiovascular risk. HDL (high-density lipoprotein), or “good cholesterol,” helps remove cholesterol from the bloodstream. Triglycerides are the main form of fat in the blood, reflecting how your body stores and uses energy. ApoB is a protein found on LDL and other atherogenic particles, serving as a direct count of particles that can contribute to plaque buildup. LDL-P and HDL-P measure the number of LDL and HDL particles, while LDL Size and HDL Size describe the average size of these particles, which can influence their behavior in the body.A stable and healthy lipid profile—characterized by optimal levels and particle sizes—supports resilient blood vessels, efficient energy use, and balanced hormone production. Dyslipidemia, or abnormal lipid levels, can signal increased risk for atherosclerosis, metabolic syndrome, and other systemic imbalances.Interpretation of these biomarkers can be influenced by factors such as age, sex, pregnancy, acute illness, certain medications, and laboratory methods. These variables are important to consider when assessing lipid health.

FAQs

It measures how fats are carried in your blood and whether those particles promote or protect against artery plaque. Beyond basic cholesterol, it looks at particle number and size, which reflect cardiovascular burden and metabolic health. Superpower tests your blood for LDL, HDL, Triglycerides, ApoB, LDL-P, HDL-P, LDL Size, and HDL Size. LDL and ApoB indicate atherogenic load (particle count). HDL and HDL-P reflect reverse cholesterol transport. Triglycerides signal remnant lipoproteins and insulin resistance. Particle sizes show how triglyceride-rich your system is and whether LDL skews smaller and denser.

It clarifies your true atherogenic burden and metabolic pattern, not just total cholesterol. ApoB and LDL-P quantify the number of artery-entering particles, the key engine of plaque. Triglycerides and particle sizes uncover insulin resistance and remnant lipoproteins. HDL measures add context for cholesterol efflux. Together, these markers show how your lipid transport system is functioning and refine cardiovascular risk estimation, enabling earlier detection of risk patterns that basic lipids can miss.

Yes. With Superpower, our team member can organize a professional blood draw in your home.

Get a baseline, then recheck at intervals that track stability or change. Many adults repeat testing annually if stable. When results are changing—after medication changes, major weight shifts, or new diagnoses—testing every 3–12 months is common until the pattern is clear. Advanced markers like ApoB or LDL-P are useful for confirming sustained improvement or detecting silent risk despite “normal” LDL-C. Frequency ultimately depends on overall cardiovascular risk and clinical context.

Recent meals (especially refined carbs and alcohol) raise triglycerides and shift LDL smaller. Acute illness, inflammation, pregnancy, and intense exercise transiently alter values. Medications (statins, fibrates, omega-3s, niacin, steroids, some diuretics), thyroid status, diabetes, kidney or liver disease, and smoking influence particle numbers and composition. Weight change and menopause matter. Genetics (e.g., familial hypercholesterolemia, elevated Lp(a), hypertriglyceridemia variants) can dominate patterns regardless of lifestyle.

Fasting 8–12 hours is recommended (water is fine), especially to stabilize triglycerides and particle metrics, though non‑fasting panels are acceptable in many settings. Avoid alcohol for 24 hours. Take routine medications unless your clinician advises otherwise. Try to test when you’re not acutely ill. Superpower will guide scheduling and collection so your LDL, HDL, Triglycerides, ApoB, LDL-P, HDL-P, LDL Size, and HDL Size are measured under consistent conditions.

References

  1. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., ... Wiklund, O. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455
  2. Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
  3. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
  4. Emerging Risk Factors Collaboration. (2009). Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302(18), 1993-2000. https://doi.org/10.1001/jama.2009.1619
  5. Garg, R., & Rustagi, T. (2018). Management of hypertriglyceridemia induced acute pancreatitis. BioMed Research International, 2018, 4721357. https://doi.org/10.1155/2018/4721357

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey